Cita APA (7a ed.)
MIRASOL, F. (2022). Streamlining Bulk mAb Manufacturing: The projected growth in the biosimilars market will require increased bulk mAb manufacturing. BioPharm International, 35(9), 20-23.
Cita Chicago Style (17a ed.)
MIRASOL, FELIZA. "Streamlining Bulk MAb Manufacturing: The Projected Growth in the Biosimilars Market Will Require Increased Bulk MAb Manufacturing." BioPharm International 35, no. 9 (2022): 20-23.
Cita MLA (9a ed.)
MIRASOL, FELIZA. "Streamlining Bulk MAb Manufacturing: The Projected Growth in the Biosimilars Market Will Require Increased Bulk MAb Manufacturing." BioPharm International, vol. 35, no. 9, 2022, pp. 20-23.
Precaución: Estas citas no son 100% exactas.